EMFLAZA is a Oral Suspension in the Human Prescription Drug category. It is labeled and distributed by Marathon Pharmaceuticals, Llc. The primary component is Deflazacort.
Product ID | 42998-505_4e001bac-ce04-4262-96f4-8b23161f9e55 |
NDC | 42998-505 |
Product Type | Human Prescription Drug |
Proprietary Name | EMFLAZA |
Generic Name | Deflazacort |
Dosage Form | Suspension |
Route of Administration | ORAL |
Marketing Start Date | 2017-02-09 |
Marketing End Date | 2020-06-30 |
Marketing Category | NDA / NDA |
Application Number | NDA208685 |
Labeler Name | Marathon Pharmaceuticals, LLC |
Substance Name | DEFLAZACORT |
Active Ingredient Strength | 23 mg/mL |
Pharm Classes | Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA] |
NDC Exclude Flag | N |
Marketing Start Date | 2017-02-09 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA208685 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2017-02-09 |
Marketing End Date | 2020-06-30 |
Ingredient | Strength |
---|---|
DEFLAZACORT | 22.75 mg/mL |
SPL SET ID: | c1d8a24e-96d4-4e3a-8f7e-b9c2dc060b1f |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
42998-501 | EMFLAZA | deflazacort |
42998-502 | EMFLAZA | deflazacort |
42998-503 | EMFLAZA | deflazacort |
42998-504 | EMFLAZA | deflazacort |
42998-505 | EMFLAZA | deflazacort |
52856-501 | EMFLAZA | deflazacort |
52856-502 | EMFLAZA | deflazacort |
52856-503 | EMFLAZA | deflazacort |
52856-504 | EMFLAZA | deflazacort |
52856-505 | EMFLAZA | deflazacort |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
EMFLAZA 86639624 5261599 Live/Registered |
PTC THERAPEUTICS, INC. 2015-05-22 |